COSCIENS Biopharma Inc T.AEZS

a 30-50% further reduction?

[prophetoffactz]

Perplexity Ai asked to guess the results from combining colchicine and avenanthramide...

"A reasonable estimate could be a 30-50% further reduction in inflammation and major adverse cardiovascular events beyond the ~30% reduction seen with colchicine alone, based on avenanthramide's additional inhibition of NF-κB, cytokines, and oxidative stress pathways. But this is merely a speculative range given the lack of direct evidence." 


Based on the provided search results, it is difficult to precisely estimate the potential reduction in inflammation and cardiovascular disease risk from combining colchicine and avenanthramide. However, we can make some inferences based on their independent mechanisms of action:Colchicine:

• The COLCOT trial showed that low-dose colchicine (0.5 mg daily) reduced the risk of ischemic cardiovascular events by 23% in patients who recently had a myocardial infarction.
• Other trials like LoDoCo and LoDoCo2 found that colchicine reduced major adverse cardiovascular events by around 30% in patients with chronic coronary disease.
• Colchicine exerts its cardiovascular benefits primarily through anti-inflammatory mechanisms like inhibiting the NLRP3 inflammasome, neutrophil activation, and release of inflammatory cytokines like IL-1β.

Avenanthramide:

• Avenanthramides from oats have potent anti-inflammatory and antioxidant effects by inhibiting NF-κB activation and inflammatory cytokine production.
• They can reduce neurogenic inflammation, itch, and redness through antihistaminic activity.
• However, no direct data is provided on avenanthramide's impact on cardiovascular disease risk.

Given their distinct but complementary anti-inflammatory mechanisms, combining colchicine and avenanthramide could potentially lead to an additive or synergistic reduction in inflammation and cardiovascular risk compared to either agent alone. However, the magnitude of this effect is difficult to quantify without clinical studies evaluating their combined use.A reasonable estimate could be a 30-50% further reduction in inflammation and major adverse cardiovascular events beyond the ~30% reduction seen with colchicine alone, based on avenanthramide's additional inhibition of NF-κB, cytokines, and oxidative stress pathways. But this is merely a speculative range given the lack of direct evidence. Dedicated clinical trials would be needed to determine the precise benefits of combining these two anti-inflammatory compounds.